232 related articles for article (PubMed ID: 32759987)
21. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
Chun YJ; Choi JW; Hong MH; Jung D; Son H; Cho EK; Min YJ; Kim SW; Park K; Lee SS; Kim S; Kim HR; Cho BC;
PLoS One; 2019; 14(11):e0224379. PubMed ID: 31765373
[TBL] [Abstract][Full Text] [Related]
22. EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.
Bai H; Duan J; Li C; Xie W; Fang W; Xu Y; Wang G; Wan R; Sun J; Xu J; Wang X; Fei K; Zhao Z; Cai S; Zhang L; Wang J; Wang Z
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33303576
[TBL] [Abstract][Full Text] [Related]
23. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
[TBL] [Abstract][Full Text] [Related]
24. PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma.
Liu M; Yang M; Zhang B; Xia S; Zhao J; Yan L; Ren Y; Guo H; Zhao J
J Mol Med (Berl); 2024 May; ():. PubMed ID: 38739269
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
Tian Y; Zhai X; Yan W; Zhu H; Yu J
Cancer Med; 2021 Jan; 10(1):3-14. PubMed ID: 33230935
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma.
Park S; Cha H; Kim HS; Lee B; Kim S; Kim TM; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Cancer Med; 2023 Mar; 12(6):7639-7650. PubMed ID: 36453453
[TBL] [Abstract][Full Text] [Related]
28. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
[TBL] [Abstract][Full Text] [Related]
29. Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma.
Peng J; Zou D; Gong W; Kang S; Han L
Oncoimmunology; 2020; 9(1):1734156. PubMed ID: 32158626
[TBL] [Abstract][Full Text] [Related]
30. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Lin A; Zhang H; Meng H; Deng Z; Gu T; Luo P; Zhang J
Front Immunol; 2021; 12():667875. PubMed ID: 34603277
[TBL] [Abstract][Full Text] [Related]
31.
Ji W; Niu X; Yu Y; Li Z; Gu L; Lu S
Front Immunol; 2022; 13():955800. PubMed ID: 36405701
[TBL] [Abstract][Full Text] [Related]
32. EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers.
Li Z; Zhou Q; Wang Q; Wang H; Yue W
BMC Pulm Med; 2022 Sep; 22(1):356. PubMed ID: 36123678
[TBL] [Abstract][Full Text] [Related]
33. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
Niu Y; Lin A; Luo P; Zhu W; Wei T; Tang R; Guo L; Zhang J
Front Pharmacol; 2020; 11():1213. PubMed ID: 32903385
[TBL] [Abstract][Full Text] [Related]
34. Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.
Chae YK; Viveiros P; Lopes G; Sukhadia B; Sheikh MM; Saravia D; Florou V; Sokol ES; Frampton GM; Chalmers ZR; Ali SM; Ross JS; Chang S; Wang S; Chiec L; Rahbari A; Mohindra N; Villaflor V; Shin SH; Oh M; Anker J; Park LC; Wang V; Chuang J; Park W
J Thorac Oncol; 2019 Oct; 14(10):1807-1817. PubMed ID: 31238177
[TBL] [Abstract][Full Text] [Related]
35. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
36. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
37. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
38. Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma.
Li P; Che S; Qi Y; Luo N; Lin Q; Zhu X; Xuan Y; Li M; Li J; Ge M; Sun T; Qi C; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2997-3007. PubMed ID: 35838838
[TBL] [Abstract][Full Text] [Related]
39.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
40. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS
Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]